Molecular Mechanisms of Lithium Action: Switching the Light on Multiple Targets for Dementia Using Animal Models

Frontiers in Molecular Neuroscience

Volumn 11, Issue , 2018, Pages

  Kerr, Fiona ^a   Bjedov, Ivana ^b   Sofola Adesakin, Oyinkan ^c  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Dementia; GSK 3; Lithium; Neuro inflammation; Neurogenesis; Oxidative damage; Proteostasis; Synaptic maintenance

Indexed keywords

EID: 85054875049     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2018.00297     Document Type: Article

References (170)

1. Abed D. A., Goldstein M., Albanyan H., Jin H., Hu L., (2015). Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm. Sin. B 5, 285–299. 10.1016/j.apsb.2015.05.00826579458.
2. Acharya J. K., Labarca P., Delgado R., Jalink K., Zuker C. S., (1998). Synaptic defects and compensatory regulation of inositol metabolism in inositol polyphosphate 1-phosphatase mutants. Neuron 20, 1219–1229. 10.1016/s0896-6273(00)80502-49655509.
3. Aghdam S. Y., Barger S. W., (2007). Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr. Alzheimer Res. 4, 21–31. 10.2174/15672050777993983217316163.
4. Alfieri A., Srivastava S., Siow R. C. M., Modo M., Fraser P. A., Mann G. E., (2011). Targeting the Nrf2-Keap1 antioxidant defence pathway for neurovascular protection in stroke. J. Physiol. 589, 4125–4136. 10.1113/jphysiol.2011.21029421646410.
5. Atack J. R., Cook S. M., Watt A. P., Fletcher S. R., Ragan C. I., (1993). In vitro and In vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J. Neurochem. 60, 652–658. 10.1111/j.1471-4159.1993.tb03197.x8380439.
6. Balchin D., Hayer-Hartl M., Hartl F. U., (2016). In vivo aspects of protein folding and quality control. Science 353:aac4354. 10.1126/science.aac435427365453.
7. Barone M. C., Sykiotis G. P., Bohmann D., (2011). Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson’s disease. Dis. Model. Mech. 4, 701–707. 10.1242/dmm.00757521719443.
8. Basselin M., Kim H.-W., Chen M., Ma K., Rapoport S. I., Murphy R. C.. (2010). Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J. Lipid Res. 51, 1049–1056. 10.1194/jlr.m00246920040630.
9. Basselin M., Villacreses N. E., Lee H.-J., Bell J. M., Rapoport S. I., (2007). Chronic lithium administration attenuates up-regulated brain arachidonic acid metabolism in a rat model of neuroinflammation. J. Neurochem. 102, 761–772. 10.1111/j.1471-4159.2007.04593.x17488274.
10. Baxter P. S., Hardingham G. E., (2016). Adaptive regulation of the brain’s antioxidant defences by neurons and astrocytes. Free Radic. Biol. Med. 100, 147–152. 10.1016/j.freeradbiomed.2016.06.02727365123.
11. Berg W. E., (1968). Effect of lithium on the rate of protein synthesis in the sea urchin embryo. Exp. Cell Res. 50, 133–139. 10.1016/0014-4827(68)90401-15650856.
12. Berridge M. J., (1993). Inositol trisphosphate and calcium signalling. Nature 361, 315–325. 10.1038/361315a08381210.
13. Berridge M. J., (2009). Inositol trisphosphate and calcium signalling mechanisms. Biochim. Biophys. Acta 1793, 933–940. 10.1016/j.bbamcr.2008.10.00519010359.
14. Berridge M. J., Downes C. P., Hanley M. R., (1989). Neural and developmental actions of lithium: a unifying hypothesis. Cell 59, 411–419. 10.1016/0092-8674(89)90026-32553271.
15. Berry G. T., Buccafusca R., Greer J. J., Eccleston E., (2004). Phosphoinositide deficiency due to inositol depletion is not a mechanism of lithium action in brain. Mol. Genet. Metab. 82, 87–92. 10.1016/j.ymgme.2004.02.00215110328.
16. Beurel E., Jope R. S., (2008). Differential regulation of STAT family members by glycogen synthase kinase-3. J. Biol. Chem. 283, 21934–21944. 10.1074/jbc.m80248120018550525.
17. Bosetti F., Seemann R., Rapoport S. I., (2002). Chronic lithium chloride administration to rats decreases brain protein level of epsilon (ε) subunit of eukaryotic initiation factor-2B. Neurosci. Lett. 327, 71–73. 10.1016/s0304-3940(02)00354-312098503.
18. Bruns D. R., Drake J. C., Biela L. M., Peelor F. F., Miller B. F., Hamilton K. L., (2015). Nrf2 signaling and the slowed aging phenotype: evidence from long-lived models. Oxid. Med. Cell. Longev. 2015:732596. 10.1155/2015/73259626583062.
19. Budni J., Feijó D. P., Batista-Silva H., Garcez M. L., Mina F., Belletini-Santos T.. (2017). Lithium and memantine improve spatial memory impairment and neuroinflammation induced by β-amyloid 1–42 oligomers in rats. Neurobiol. Learn. Mem. 141, 84–92. 10.1016/j.nlm.2017.03.01728359852.
20. Calsolaro V., Edison P., (2016). Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement. 12, 719–732. 10.1016/j.jalz.2016.02.01027179961.
21. Campolo M., Casili G., Lanza M., Filippone A., Paterniti I., Cuzzocrea S.. (2018). Multiple mechanisms of dimethyl fumarate in amyloid β-induced neurotoxicity in human neuronal cells. J. Cell. Mol. Med. 22, 1081–1094. 10.1111/jcmm.1335828990726.
22. Can A., Schulze T. G., Gould T. D., (2014). Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol. Biochem. Behav. 123, 3–16. 10.1016/j.pbb.2014.02.00424534415.
23. Cao Y., Chtarbanova S., Petersen A. J., Ganetzky B., (2013). Dnr1 mutations cause neurodegeneration in Drosophila by activating the innate immune response in the brain. Proc. Natl. Acad. Sci. U S A 110, E1752–E1760. 10.1073/pnas.130622011023613578.
24. Castillo-Quan J. I., Li L., Kinghorn K. J., Ivanov D. K., Tain L. S., Slack C.. (2016). Lithium promotes longevity through GSK3/NRF2-dependent hormesis. Cell Rep. 15, 638–650. 10.1016/j.celrep.2016.03.04127068460.
25. Castro A. A., Casagrande T. S., Moretti M., Constantino L., Petronilho F., Guerra G. C. B.. (2009). Lithium attenuates behavioral and biochemical effects of neuropeptide S in mice. Peptides 30, 1914–1920. 10.1016/j.peptides.2009.07.00419616051.
26. Chen R. W., Chuang D. M., (1999). Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. 274, 6039–6042. 10.1074/jbc.274.10.603910037682.
27. Chen Y., Liang Z., Blanchard J., Dai C.-L., Sun S., Lee M. H.. (2013). A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol. Neurobiol. 47, 711–725. 10.1007/s12035-012-8375-523150171.
28. Chen X., Liu Y., Zhu J., Lei S., Dong Y., Li L.. (2016). GSK-3β downregulates Nrf2 in cultured cortical neurons and in a rat model of cerebral ischemia-reperfusion. Sci. Rep. 6:20196. 10.1038/srep2019626838164.
29. Chen G., Rajkowska G., Du F., Seraji-Bozorgzad N., Manji H. K., (2000). Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75, 1729–1734. 10.1046/j.1471-4159.2000.0751729.x10987856.
30. Chen P.-C., Vargas M. R., Pani A. K., Smeyne R. J., Johnson D. A., Kan Y. W.. (2009). Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte. Proc. Natl. Acad. Sci. U S A 106, 2933–2938. 10.1073/pnas.081336110619196989.
31. Cheng Y., Pardo M., Armini R. S., Martinez A., Mouhsine H., Zagury J.-F.. (2016). Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain Behav. Immun. 53, 207–222. 10.1016/j.bbi.2015.12.01226772151.
32. Chin P. C., Majdzadeh N., D’Mello S. R., (2005). Inhibition of GSK3β is a common event in neuroprotection by different survival factors. Mol. Brain Res. 137, 193–201. 10.1016/j.molbrainres.2005.03.00415950778.
33. Chiu C.-T., Liu G., Leeds P., Chuang D.-M., (2011). Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington’s disease. Neuropsychopharmacology 36, 2406–2421. 10.1038/npp.2011.12821796107.
34. Choi C. H., Schoenfeld B. P., Bell A. J., Hinchey P., Kollaros M., Gertner M. J.. (2011). Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Res. 1380, 106–119. 10.1016/j.brainres.2010.11.03221078304.
35. Cryns K., Shamir A., Shapiro J., Daneels G., Goris I., Van Craenendonck H.. (2007). Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology 32, 881–891. 10.1038/sj.npp.130115416841073.
36. Cuadrado A., Kügler S., Lastres-Becker I., (2018). Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biol. 14, 522–534. 10.1016/j.redox.2017.10.01029121589.
37. Cunha C., Brambilla R., Thomas K. L., (2010). A simple role for BDNF in learning and memory? Front. Mol. Neurosci. 3:1. 10.3389/neuro.02.001.201020162032.
38. Damri O., Sade Y., Toker L., Bersudsky Y., Belmaker R. H., Agam G.. (2015). Molecular effects of lithium are partially mimicked by inositol-monophosphatase (IMPA)1 knockout mice in a brain region-dependent manner. Eur. Neuropsychopharmacol. 25, 425–434. 10.1016/j.euroneuro.2014.06.01225748680.
39. DaRocha-Souto B., Coma M., Pérez-Nievas B. G., Scotton T. C., Siao M., Sánchez-Ferrer P.. (2012). Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer’s disease. Neurobiol. Dis. 45, 425–437. 10.1016/j.nbd.2011.09.00221945540.
40. De Ferrari G. V., Chacón M. A., Barría M. I., Garrido J. L., Godoy J. A., Olivares G.. (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils. Mol. Psychiatry 8, 195–208. 10.1038/sj.mp.400120812610652.
41. De Paola M., Sestito S. E., Mariani A., Memo C., Fanelli R., Freschi M.. (2016). Synthetic and natural small molecule TLR4 antagonists inhibit motoneuron death in cultures from ALS mouse model. Pharmacol. Res. 103, 180–187. 10.1016/j.phrs.2015.11.02026640075.
42. Douglas P. M., Dillin A., (2010). Protein homeostasis and aging in neurodegeneration. J. Cell Biol. 190, 719–729. 10.1083/jcb.20100514420819932.
43. Dumont M., Wille E., Calingasan N. Y., Tampellini D., Williams C., Gouras G. K.. (2009). Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer’s disease. J. Neurochem. 109, 502–512. 10.1111/j.1471-4159.2009.05970.x19200343.
44. Eldar-Finkelman H., Martinez A., (2011). GSK-3 inhibitors: preclinical and clinical focus on CNS. Front. Mol. Neurosci. 4:32. 10.3389/fnmol.2011.0003222065134.
45. Farina F., Lambert E., Commeau L., Lejeune F. X., Roudier N., Fonte C.. (2017). The stress response factor daf-16/FOXO is required for multiple compound families to prolong the function of neurons with Huntington’s disease. Sci. Rep. 7:4014. 10.1038/s41598-017-04256-w28638078.
46. Farr S. A., Ripley J. L., Sultana R., Zhang Z., Niehoff M. L., Platt T. L.. (2014). Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic. Biol. Med. 67, 387–395. 10.1016/j.freeradbiomed.2013.11.01424355211.
47. Fernandes B. S., Molendijk M. L., Köhler C. A., Soares J. C., Leite C. M. G. S., Machado-Vieira R.. (2015). Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med. 13:289. 10.1186/s12916-015-0529-726621529.
48. Fiorentini A., Rosi M. C., Grossi C., Luccarini I., Casamenti F., (2010). Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mice. PLoS One 5:e14382. 10.1371/journal.pone.001438221187954.
49. Fletcher S., Page B. D. G., Zhang X., Yue P., Li Z. H., Sharmeen S.. (2011). Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. ChemMedChem 6, 1459–1470. 10.1002/cmdc.20110019421618433.
50. Fornai F., Longone P., Cafaro L., Kastsiuchenka O., Ferrucci M., Manca M. L.. (2008a). Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U S A 105, 2052–2057. 10.1073/pnas.070802210518250315.
51. Fornai F., Longone P., Ferrucci M., Lenzi P., Isidoro C., Ruggieri S.. (2008b). Autophagy and amyotrophic lateral sclerosis: the multiple roles of lithium. Autophagy 4, 527–530. 10.4161/auto.592318367867.
52. Fowler J. H., McQueen J., Holland P. R., Manso Y., Marangoni M., Scott F.. (2017). Dimethyl fumarate improves white matter function following severe hypoperfusion: involvement of microglia/macrophages and inflammatory mediators. J. Cereb. Blood Flow Metab. 38, 1354–1370. 10.1177/0271678x1771310528606007.
53. Frake R. A., Menzies F. M., David C., Invest J. C., Frake R. A., Ricketts T.. (2015). Autophagy and neurodegeneration. J. Clin. Invest. 125, 65–74. 10.1172/JCI7394425654552.
54. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., Yamawaki S., (2001). Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology 158, 100–106. 10.1007/s00213010087111685390.
55. Galluzzi L., Bravo-San Pedro J. M., Levine B., Green D. R., Kroemer G., (2017). Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat. Rev. Drug Discov. 16, 487–511. 10.1038/nrd.2017.2228529316.
56. Gelfo F., Cutuli D., Nobili A., De Bartolo P., D’Amelio M., Petrosini L.. (2017). Chronic lithium treatment in a rat model of basal forebrain cholinergic depletion: effects on memory impairment and neurodegeneration. J. Alzheimer’s Dis. 56, 1505–1518. 10.3233/jad-16089228222508.
57. Gideons E. S., Lin P. Y., Mahgoub M., Kavalali E. T., Monteggia L. M., (2017). Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling. Elife 6:e25480. 10.7554/elife.2548028621662.
58. Green H. F., Nolan Y. M., (2012). GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia. Neurochem. Int. 61, 666–671. 10.1016/j.neuint.2012.07.00322796213.
59. Guo J., Cheng J., North B. J., Wei W., (2017). Functional analyses of major cancer-related signaling pathways in Alzheimer’s disease etiology. Biochim. Biophys. Acta 1868, 341–358. 10.1016/j.bbcan.2017.07.00128694093.
60. Gurvich N., Klein P. S., (2002). Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96, 45–66. 10.1016/s0163-7258(02)00299-112441177.
61. Haas L. T., Salazar S. V., Smith L. M., Zhao H. R., Cox T. O., Herber C. S.. (2017). Silent allosteric modulation of mglur5 maintains glutamate signaling while rescuing Alzheimer’s mouse phenotypes. Cell Rep. 20, 76–88. 10.1016/j.celrep.2017.06.02328683325.
62. Habib A., Sawmiller D., Li S., Xiang Y., Rongo D., Tian J.. (2017). LISPRO mitigates β-amyloid and associated pathologies in Alzheimer’s mice. Cell Death Dis. 8:e2880. 10.1038/cddis.2017.27928617434.
63. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R.. (2006). Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885–889. 10.1038/nature0472416625204.
64. Hashimoto R., Takei N., Shimazu K., Christ L., Lu B., Chuang D. M., (2002). Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43, 1173–1179. 10.1016/s0028-3908(02)00217-412504924.
65. Hosseini S., Wilk E., Michaelsen-Preusse K., Gerhauser I., Baumgärtner W., Geffers R.. (2018). Long-term neuroinflammation induced by influenza a virus infection and the impact on hippocampal neuron morphology and function. J. Neurosci. 38, 3060–3080. 10.1523/jneurosci.1740-17.201829487124.
66. Huber K. M., Gallagher S. M., Warren S. T., Bear M. F., (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U S A 99, 7746–7750. 10.1073/pnas.12220569912032354.
67. Iadecola C., (2013). The pathobiology of vascular dementia. Neuron 80, 844–866. 10.1016/j.neuron.2013.10.00824267647.
68. Jang S.-W., Liu X., Yepes M., Shepherd K. R., Miller G. W., Liu Y.. (2010). A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc. Natl. Acad. Sci. U S A 107, 2687–2692. 10.1073/pnas.091357210720133810.
69. Jin K., Galvan V., Xie L., Mao X. O., Gorostiza O. F., Bredesen D. E.. (2004). Enhanced neurogenesis in Alzheimer’s disease transgenic (PDGF-APPSw,Ind) mice. Proc. Natl. Acad. Sci. U S A 101, 13363–13367. 10.1073/pnas.040367810115340159.
70. Jope R. S., Cheng Y., Lowell J. A., Worthen R. J., Sitbon Y. H., Beurel E., (2017). Stressed and inflamed, can GSK3 be blamed? Trends Biochem. Sci. 42, 180–192. 10.1016/j.tibs.2016.10.00927876551.
71. Jovanovic J. N., Czernik A. J., Fienberg A. A., Greengard P., Sihra T. S., (2000). Synapsins as mediators of BDNF-enhanced neurotransmitter release. Nat. Neurosci. 3, 323–329. 10.1038/7388810725920.
72. Jung C. H., Ro S.-H., Cao J., Otto N. M., Kim D.-H., (2010). mTOR regulation of autophagy. FEBS Lett. 584, 1287–1295. 10.1016/j.febslet.2010.01.01720083114.
73. Kanninen K., Heikkinen R., Malm T., Rolova T., Kuhmonen S., Leinonen H.. (2009). Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 106, 16505–16510. 10.1073/pnas.090839710619805328.
74. Kanninen K., White A. R., Koistinaho J., Malm T., (2011). Targeting glycogen synthase kinase-3β for therapeutic benefit against oxidative stress in Alzheimer’s disease: involvement of the Nrf2-ARE pathway. Int. J. Alzheimers Dis. 2011:985085. 10.4061/2011/98508521629716.
75. Karyo R., Eskira Y., Pinhasov A., Belmaker R. H., Agam G., Eldar-Finkelman Hagit H., (2010). Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Mol. Cell. Neurosci. 45, 449–455. 10.1016/j.mcn.2010.08.00420708687.
76. Kasuya J., Kaas G., Kitamoto T., (2009). Effects of lithium chloride on the gene expression profiles in Drosophila heads. Neurosci. Res. 64, 413–420. 10.1016/j.neures.2009.04.01519410610.
77. Kawabori M., Yenari M. A., (2015). Inflammatory responses in brain ischemia. Curr. Med. Chem. 22, 1258–1277. 10.2174/092986732266615020915403625666795.
78. Kerr F., Sofola-Adesakin O., Ivanov D. K., Gatliff J., Gomez Perez-Nievas B., Bertrand H. C.. (2017). Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease. PLoS Genet. 13:e1006593. 10.1371/journal.pgen.100659328253260.
79. Khan A., Jamwal S., Bijjem K. R. V., Prakash A., Kumar P., (2015). Neuroprotective effect of hemeoxygenase-1/glycogen synthase kinase-3β modulators in 3-nitropropionic acid-induced neurotoxicity in rats. Neuroscience 287, 66–77. 10.1016/j.neuroscience.2014.12.01825536048.
80. Khurana V., Lu Y., Steinhilb M. L., Oldham S., Shulman J. M., Feany M. B., (2006). TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr. Biol. 16, 230–241. 10.1016/j.cub.2005.12.04216461276.
81. Kim H. J., Thayer S. A., (2009). Lithium increases synapse formation between hippocampal neurons by depleting phosphoinositides. Mol. Pharmacol. 75, 1021–1030. 10.1124/mol.108.05235719188338.
82. King M. K., Jope R. S., (2013). Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome. Genes Brain Behav. 12, 723–731. 10.1111/gbb.1207123941202.
83. Klein P. S., Melton D. A., (1996). A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U S A 93, 8455–8459. 10.1073/pnas.93.16.84558710892.
84. Klionsky D., Agholme L., Agnello M., Agostinis P., Aguirre-ghiso J. A., Ahn H. J.. (2016). Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8, 445–544. 10.4161/auto.19496.
85. Kluck R. M., Bossy-Wetzel E., Green D. R., Newmeyer D. D., (1997). The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275, 1132–1136. 10.1126/science.275.5303.11329027315.
86. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J. I., Tanida I.. (2006). Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880–884. 10.1038/nature0472316625205.
87. Kremer A., Louis J. V., Jaworski T., Van Leuven F., (2011). GSK3 and Alzheimer’s disease: facts and fiction‥. Front. Mol. Neurosci. 4:17. 10.3389/fnmol.2011.0001721904524.
88. Krstic D., Madhusudan A., Doehner J., Vogel P., Notter T., Imhof C.. (2012). Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflammation 9:151. 10.1186/1742-2094-9-15122747753.
89. Kudo W., Lee H.-P., Smith M. A., Zhu X., Matsuyama S., Lee H.-G., (2012). Inhibition of Bax protects neuronal cells from oligomeric Aβ neurotoxicity. Cell Death Dis. 3:e309. 10.1038/cddis.2012.4322592316.
90. Kumar A., Dhull D. K., Mishra P. S., (2015). Therapeutic potential of mGluR5 targeting in Alzheimer’s disease. Front. Neurosci. 9:215. 10.3389/fnins.2015.0021526106290.
91. Lastres-Becker I., García-Yagüe A. J., Scannevin R. H., Casarejos M. J., Kügler S., Rábano A.. (2016). Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson’s disease. Antioxid. Redox Signal. 25, 61–77. 10.1089/ars.2015.654927009601.
92. Li H., Li Q., Du X., Sun Y., Wang X., Kroemer G.. (2011). Lithium-mediated long-term neuroprotection in neonatal rat hypoxia-ischemia is associated with antiinflammatory effects and enhanced proliferation and survival of neural stem/progenitor cells. J. Cereb. Blood Flow Metab. 31, 2106–2115. 10.1038/jcbfm.2011.7521587270.
93. Lieu C. A., Dewey C. M., Chinta S. J., Rane A., Rajagopalan S., Batir S.. (2014). Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model. Brain Res. 1591, 111–117. 10.1016/j.brainres.2014.10.03225452026.
94. Lin A.-L., Jahrling J. B., Zhang W., DeRosa N., Bakshi V., Romero P.. (2017). Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease. J. Cereb. Blood Flow Metab. 37, 217–226. 10.1177/0271678x1562157526721390.
95. Lionaki E., Markaki M., Palikaras K., Tavernarakis N., (2015). Mitochondria, autophagy and age-associated neurodegenerative diseases: new insights into a complex interplay. Biochim. Biophys. Acta 1847, 1412–1423. 10.1016/j.bbabio.2015.04.01025917894.
96. Liu Z.-H., Chuang D.-M., Smith C. B., (2011). Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int. J. Neuropsychopharmacol. 14, 618–630. 10.1017/s146114571000052020497624.
97. Liu Z. H., Huang T., Smith C. B., (2012). Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome. Neurobiol. Dis. 45, 1145–1152. 10.1016/j.nbd.2011.12.03722227453.
98. Llorens-Martín M., Jurado J., Hernández F., Avila J., (2014). GSK-3β, a pivotal kinase in Alzheimer disease. Front. Mol. Neurosci. 7:46. 10.3389/fnmol.2014.0004624904272.
99. Lovestone S., Boada M., Dubois B., Hüll M., Rinne J. O., Huppertz H.-J.. (2015). A Phase II trial of Tideglusib in Alzheimer’s disease. J. Alzheimers Dis. 45, 75–88. 10.3233/JAD-14195925537011.
100. Lu S.-M., Gui B., Dong H.-Q., Zhang X., Zhang S.-S., Hu L.-Q.. (2015). Prophylactic lithium alleviates splenectomy-induced cognitive dysfunction possibly by inhibiting hippocampal TLR4 activation in aged rats. Brain Res. Bull. 114, 31–41. 10.1016/j.brainresbull.2015.02.00825839444.
101. Lucas J. J., Hernández F., Gómez-Ramos P., Morán M. A., Hen R., Avila J., (2001). Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20, 27–39. 10.1093/emboj/20.1.2711226152.
102. Lüscher C., Huber K. M., (2010). Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 65, 445–459. 10.1016/j.neuron.2010.01.01620188650.
103. McBride S. M. J., Choi C. H., Wang Y., Liebelt D., Braunstein E., Ferreiro D.. (2005). Pharmacological rescue of synaptic plasticity, courtship behavior and mushroom body defects in a Drosophila model of Fragile X syndrome. Neuron 45, 753–764. 10.1016/j.neuron.2005.01.03815748850.
104. McColl G., Killilea D. W., Hubbard A. E., Vantipalli M. C., Melov S., Lithgow G. J., (2008). Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans. J. Biol. Chem. 283, 350–357. 10.1074/jbc.m70502820017959600.
105. Menzies F. M., Fleming A., Caricasole A., Bento C. F., Andrews S. P., Ashkenazi A.. (2017). Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron 93, 1015–1034. 10.1016/j.neuron.2017.01.02228279350.
106. Mizushima N., Komatsu M., (2011). Autophagy: renovation of cells and tissues. Cell 147, 728–741. 10.1016/j.cell.2011.10.02622078875.
107. Morris G., Berk M., (2016). The putative use of lithium in Alzheimer’s disease. Curr. Alzheimer Res. 13, 853–861. 10.2174/156720501366616021911311226892287.
108. Motoi Y., Shimada K., Ishiguro K., Hattori N., (2014). Lithium and autophagy. ACS Chem. Neurosci. 5, 434–442. 10.1021/cn50005624738557.
109. Mudher A., Shepherd D., Newman T. A., Mildren P., Jukes J. P., Squire A.. (2004). GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psychiatry 9, 522–530. 10.1038/sj.mp.400148314993907.
110. Nazem A., Sankowski R., Bacher M., Al-Abed Y., (2015). Rodent models of neuroinflammation for Alzheimer’s disease. J. Neuroinflammation 12:74. 10.1186/s12974-015-0291-y25890375.
111. Nery L. R., Eltz N. S., Hackman C., Fonseca R., Altenhofen S., Guerra H. N.. (2014). Brain intraventricular injection of amyloid-β in zebrafish embryo impairs cognition and increases tau phosphorylation, effects reversed by lithium. PLoS One 9:e105862. 10.1371/journal.pone.010586225187954.
112. Neymotin A., Calingasan N. Y., Wille E., Naseri N., Petri S., Damiano M.. (2011). Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 51, 88–96. 10.1016/j.freeradbiomed.2011.03.027 21457778.
113. Nikoletopoulou V., Papandreou M. E., Tavernarakis N., (2015). Autophagy in the physiology and pathology of the central nervous system. Cell Death Differ. 22, 398–407. 10.1038/cdd.2014.20425526091.
114. Niswender C. M., Conn P. J., (2010). Metabotropic glutamate receptors: physiology, pharmacology and disease. Annu. Rev. Pharmacol. Toxicol. 50, 295–322. 10.1146/annurev.pharmtox.01100820055706.
115. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F.. (2005). Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U S A 102, 6990–6995. 10.1073/pnas.050046610215867159.
116. Nunes M. A., Schöwe N. M., Monteiro-Silva K. C., Baraldi-Tornisielo T., Souza S. I. G., Balthazar J.. (2015). Correction: chronic microdose lithium treatment prevented memory loss and neurohistopathological changes in a transgenic mouse model of Alzheimer’s disease. PLoS One 10:e0142267. 10.1371/journal.pone.0145695 26678744.
117. Nunes M. A., Viel T. A., Buck H. S., (2013). Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr. Alzheimer Res. 10, 104–107. 10.2174/15672051380487135422746245.
118. O’Brien W. T., Harper A. D., Jové F., Woodgett J. R., Maretto S., Piccolo S.. (2004). Glycogen synthase kinase-3 haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24, 6791–6798. 10.1523/JNEUROSCI.4753-03.200415282284.
119. O’Brien W. T., Huang J., Buccafusca R., Garskof J., Valvezan A. J., Berry G. T.. (2011). Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J. Clin. Invest. 121, 3756–3762. 10.1172/JCI4519421821916.
120. Odeya D., Galila A., Lilah T., (2018). The observed alteration in BCL2 expression following lithium treatment is influenced by the choice of normalization method. Sci. Rep. 8:6399. 10.1038/s41598-018-24546-129686228.
121. Overk C. R., Cartier A., Shaked G., Rockenstein E., Ubhi K., Spencer B.. (2014). Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 - implications for dementia with lewy bodies. Mol. Neurodegener. 9:18. 10.1186/1750-1326-9-1824885390.
122. Ozcelik S., Fraser G., Castets P., Schaeffer V., Skachokova Z., Breu K.. (2013). Rapamycin attenuates the progression of tau pathology in P301S Tau transgenic mice. PLoS One 8:e62459. 10.1371/journal.pone.006245923667480.
123. Perrin-Cocon L., Aublin-Gex A., Sestito S. E., Shirey K. A., Patel M. C., André P.. (2017). TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells and protects mice from lethal influenza infection. Sci. Rep. 7:40791. 10.1038/srep4079128106157.
124. Phiel C. J., Wilson C. A., Lee V. M.-Y., Klein P. S., (2003). GSK-3α regulates production of Alzheimer’s disease amyloid-β peptides. Nature 423, 435–439. 10.1038/nature0164012761548.
125. Pintado C., Gavilán M. P., Gavilán E., García-Cuervo L., Gutiérrez A., Vitorica J.. (2012). Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus. J. Neuroinflammation 9:87. 10.1186/1742-2094-9-8722559833.
126. Pizzasegola C., Caron I., Daleno C., Ronchi A., Minoia C., Carrì M. T.. (2009). Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph. Lateral Scler. 10, 221–228. 10.1080/17482960902803440 19308767.
127. Quiroz J. A., Machado-Vieira R., Zarate C. A., Manji H. K., (2010). Novel insights into lithium’s mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 62, 50–60. 10.1159/00031431020453535.
128. Ribeiro F. M., Vieira L. B., Pires R. G. W., Olmo R. P., Ferguson S. S. G., (2017). Metabotropic glutamate receptors and neurodegenerative diseases. Pharmacol. Res. 115, 179–191. 10.1016/j.phrs.2016.11.01327872019.
129. Rojo A. I., Rada P., Egea J., Rosa A. O., López M. G., Cuadrado A., (2008). Functional interference between glycogen synthase kinase-3 β and the transcription factor Nrf2 in protection against kainate-induced hippocampal celldeath. Mol. Cell. Neurosci. 39, 125–132. 10.1016/j.mcn.2008.06.007 18619545.
130. Roux M., Dosseto A., (2017). From direct to indirect lithium targets: a comprehensive review of omics data. Metallomics 9, 1326–1351. 10.1039/c7mt00203c28885630.
131. Sarkar S., Floto R. A., Berger Z., Imarisio S., Cordenier A., Pasco M.. (2005). Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101–1111. 10.1083/jcb.20050403516186256.
132. Sarkar S., Krishna G., Imarisio S., Saiki S., O’Kane C. J., Rubinsztein D. C., (2008). A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin. Hum. Mol. Genet. 17, 170–178. 10.1093/hmg/ddm29417921520.
133. Sarkar S., Rubinsztein D. C., (2006). Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations. Autophagy 2, 132–134. 10.4161/auto.2387.
134. Schloesser R. J., Huang J., Klein P. S., Manji H. K., (2008). Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33, 110–133. 10.1038/sj.npp.130157517912251.
135. Serenó L., Coma M., Rodríguez M., Sánchez-Ferrer P., Sánchez M. B., Gich I.. (2009). A novel GSK-3β inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 35, 359–367. 10.1016/j.nbd.2009.05.02519523516.
136. Shao L., Young L. T., Wang J.-F., (2005). Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol. Psychiatry 58, 879–884. 10.1016/j.biopsych.2005.04.05216005436.
137. 2 expression and inhibits NF-κB signaling in a mouse model of Alzheimer’s disease. Eur. J. Immunol. 46, 665–676. 10.1002/eji.201545855 26643273.
138. Shimada K., Motoi Y., Ishiguro K., Kambe T., Matsumoto S. E., Itaya M.. (2012). Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. Neurobiol. Dis. 46, 101–108. 10.1016/j.nbd.2011.12.05022249108.
139. Shin S., Wolgamott L., Tcherkezian J., Vallabhapurapu S., Yu Y., Roux P. P.. (2014). Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene 33, 1690–1699. 10.1038/onc.2013.11323584478.
140. Sofola O., Kerr F., Rogers I., Killick R., Augustin H., Gandy C.. (2010). Inhibition of GSK-3 ameliorates Aβ pathology in an adult-onset Drosophila model of Alzheimer’s disease. PLoS Genet. 6:e1001087. 10.1371/journal.pgen.1001087 20824130.
141. Sofola-Adesakin O., Castillo-Quan J. I., Rallis C., Tain L. S., Bjedov I., Rogers I.. (2014). Lithium suppresses Aβ pathology by inhibiting translation in an adult Drosophila model of Alzheimer’s disease. Front. Aging Neurosci. 6:190. 10.3389/fnagi.2014.00190 25126078.
142. Sourial-Bassillious N., Rydelius P. A., Aperia A., Aizman O., (2009). Glutamate-mediated calcium signaling: a potential target for lithium action. Neuroscience 161, 1126–1134. 10.1016/j.neuroscience.2009.04.01319362133.
143. Spilman P., Podlutskaya N., Hart M. J., Debnath J., Gorostiza O., Bredesen D.. (2010). Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer’s disease. PLoS One 5:e9979. 10.1371/journal.pone.0009979 20376313.
144. Srinivasan M., Lahiri D. K., (2015). Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer’s disease and multiple sclerosis. Expert Opin. Ther. Targets 19, 471–487. 10.1517/14728222.2014.98983425652642.
145. Sugawara H., Iwamoto K., Bundo M., Ishiwata M., Ueda J., Kakiuchi C.. (2010). Effect of mood stabilizers on gene expression in lymphoblastoid cells. J. Neural Transm. 117, 155–164. 10.1007/s00702-009-0340-819949822.
146. Sultana R., Butterfield D. A., (2010). Role of oxidative stress in the progression of Alzheimer’s disease. J. Alzheimers Dis. 19, 341–353. 10.3233/JAD-2010-122220061649.
147. Sundaram J. R., Chan E. S., Poore C. P., Pareek T. K., Cheong W. F., Shui G.. (2012). Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration. J. Neurosci. 32, 1020–1034. 10.1523/JNEUROSCI.5177-11.201222262900.
148. Suzuki H., Osawa T., Fujioka Y., Noda N. N., (2017). Structural biology of the core autophagy machinery. Curr. Opin. Struct. Biol. 43, 10–17. 10.1016/j.sbi.2016.09.01027723509.
149. Tajes M., Yeste-Velasco M., Zhu X., Chou S. P., Smith M. A., Pallàs M.. (2009). Activation of Akt by lithium: pro-survival pathways in aging. Mech. Ageing Dev. 130, 253–261. 10.1016/j.mad.2008.12.00619162061.
150. Tan H., Young L. T., Shao L., Che Y., Honer W. G., Wang J.-F., (2012). Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex. Int. J. Neuropsychopharmacol. 15, 1275–1285. 10.1017/s146114571100141621939588.
151. Tanaka K., Matsuda N., (2014). Proteostasis and neurodegeneration: the roles of proteasomal degradation and autophagy. Biochim. Biophys. Acta Mol. Cell Res. 1843, 197–204. 10.1016/j.bbamcr.2013.03.01223523933.
152. Tang S.-C., Lathia J. D., Selvaraj P. K., Jo D.-G., Mughal M. R., Cheng A.. (2008). Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid β-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol. 213, 114–121. 10.1016/j.expneurol.2008.05.01418586243.
153. Tanizawa Y., Kuhara A., Inada H., Kodama E., Mizuno T., Mori I., (2006). Inositol monophosphatase regulates localization of synaptic components and behavior in the mature nervous system of C. elegans. Genes Dev. 20, 3296–3310. 10.1101/gad.149780617158747.
154. Taupin P., (2008). Adult neurogenesis pharmacology in neurological diseases and disorders. Expert Rev. Neurother. 8, 311–320. 10.1586/14737175.8.2.31118271715.
155. Tolosa E., Litvan I., Höglinger G. U., Burn D., Lees A., Andrés M. V.. (2014). A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov. Disord. 29, 470–478. 10.1002/mds.2582424532007.
156. Tu J., Zhang X., Zhu Y., Dai Y., Li N., Yang F.. (2015). Cell-permeable peptide targeting the Nrf2-Keap1 interaction: a potential novel therapy for global cerebral ischemia. J. Neurosci. 35, 14727–14739. 10.1523/JNEUROSCI.1304-15.201526538645.
157. Um J. W., Kaufman A. C., Kostylev M., Heiss J. K., Stagi M., Takahashi H.. (2013). Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular prion protein. Neuron 79, 887–902. 10.1016/j.neuron.2013.06.03624012003.
158. Valvezan A. J., Klein P. S., (2012). GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Front. Mol. Neurosci. 5:1. 10.3389/fnmol.2012.0000122319467.
159. Vincent A. S., Roebuck-Spencer T. M., Cernich A., (2014). Cognitive changes and dementia risk after traumatic brain injury: implications for aging military personnel. Alzheimers Dement. 10, S174–S187. 10.1016/j.jalz.2014.04.00624924669.
160. Wang H.-M., Zhang T., Li Q., Huang J.-K., Chen R.-F., Sun X.-J., (2013). Inhibition of glycogen synthase kinase-3β by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes. Neurochem. Int. 63, 345–353. 10.1016/j.neuint.2013.07.00323871716.
161. Wells G., (2015). Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction. Biochem. Soc. Trans. 43, 674–679. 10.1042/bst2015005126551711.
162. Welsh G. I., Miller C. M., Loughlin A. J., Price N. T., Proud C. G., (1998). Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett. 421, 125–130. 10.1016/s0014-5793(97)01548-29468292.
163. Wilson E. N., Do Carmo S., Iulita M. F., Hall H., Ducatenzeiler A., Marks A. R.. (2017). BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology. Transl. Psychiatry 7:e1190. 10.1038/tp.2017.16928763060.
164. Wu S.-C., Cao Z.-S., Chang K.-M., Juang J.-L., (2017). Intestinal microbial dysbiosis aggravates the progression of Alzheimer’s disease in Drosophila. Nat. Commun. 8:24. 10.1038/s41467-017-00040-628634323.
165. Wurzelmann M., Romeika J., Sun D., (2017). Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury. Neural Regen. Res. 12, 7–12. 10.4103/1673-5374.198964 28250730.
166. Yu F., Wang Z., Tchantchou F., Chiu C.-T., Zhang Y., Chuang D.-M., (2012). Lithium ameliorates neurodegeneration, suppresses neuroinflammation and improves behavioral performance in a mouse model of traumatic brain injury. J. Neurotrauma 29, 362–374. 10.1089/neu.2011.1942 21895523.
167. Yuskaitis C. J., Jope R. S., (2009). Glycogen synthase kinase-3 regulates microglial migration, inflammation and inflammation-induced neurotoxicity. Cell. Signal. 21, 264–273. 10.1016/j.cellsig.2008.10.01419007880.
168. Zhang X., Heng X., Li T., Li L., Yang D., Zhang X.. (2011). Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer’s disease transgenic mouse model. J. Alzheimers Dis. 24, 739–749. 10.3233/JAD-2011-101875 21321394.
169. Zhang Z., Liu X., Schroeder J. P., Chan C.-B., Song M., Yu S. P.. (2014). 7,8-Dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 39, 638–650. 10.1038/npp.2013.243 24022672.
170. Zhu Z., Kremer P., Tadmori I., Ren Y., Sun D., He X.. (2011). Lithium suppresses astrogliogenesis by neural stem and progenitor cells by inhibiting stat3 pathway independently of glycogen synthase kinase 3 beta. PLoS One 6:e23341. 10.1371/journal.pone.002334121931595.